Clinical trial · Observational
Molecular Markers in Predicting Lung Cancer Development Using Tissue Samples From Healthy Participants
Molecular Predictors of Lung Cancer Behavior: Controls
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of blood, urine, sputum, mouth cells, and bronchial tissue from healthy participants in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about the development of cancer. PURPOSE: This laboratory study is looking for molecular markers in predicting lung cancer development using tissue samples from healthy participants.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Healthy, no Evidence of Disease | — | UNRESOLVED | — |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| biologic sample preservation procedure | Other | — | UNRESOLVED |
| bronchoscopy | Procedure | — | UNRESOLVED |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| proteomic profiling | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Healthy, non-smokers
- interventionNames
- Genetic: proteomic profiling
- Other: biologic sample preservation procedure
- Other: laboratory biomarker analysis
- Procedure: bronchoscopy
Primary outcomes (1)
- measure
- Collection of biological specimens to use as controls in the study of lung cancer progression
- timeFrame
- Off study date, up to one year
- description
- Specimens are collected from healthy participants with no known risk of lung cancer
Secondary outcomes (2)
- measure
- Identification of new molecular abnormalities specific to the development of squamous cell carcinoma of the lung
- timeFrame
- off-study date, up to one year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Healthy participant * No history of smoking * No history of cancer PATIENT CHARACTERISTICS: * SWOG performance status 0 * No clinically apparent bleeding diathesis PRIOR CONCURRENT THERAPY: * Not specified
References
Publications (0)
Data not yet available